GREY MICHAEL G 4

What Happened
Michael G. Grey, a director of OnKure Therapeutics, was granted a derivative award on June 4, 2026 covering 7,650 shares. The award was reported as acquired at a $0.00 exercise/grant price (derivative/option-type instrument) and no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-08). Filing appears timely under SEC business-day rules.
• Transaction type/code: A = Award/Grant (derivative security).
• Amount granted: 7,650 shares; reported price: $0.00.
• Shares owned after transaction: Not disclosed in this filing.
• Vesting: Footnote states 100% vests on the earlier of June 4, 2027 or the day before the issuer’s next annual meeting, subject to continued service.
• No immediate sale or exercise reported; this is a compensation grant, not a market purchase or sale.

Context
This was an equity award (option/derivative) to a director that vests up to one year from grant (or before the next annual meeting). Such grants are typically part of board compensation and do not represent an immediate purchase or sale of stock. They become economically meaningful only if and when vested options are exercised or shares are sold.